A compound according to Formula, or a pharmaceutical acceptable salt thereof, wherein, R 0 is C 1-6 alkyl; C 1-6 haloalkyl; C 1-6 hydroxyalkyl; halo-substituted C 1-6 hydroxyalkyl; or phenyl optionally substituted with 1-2 substituents independently represented by R 2; or R 0 is selected from the group C 3-7 cycloalkyl, a 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms, and a 4-6 membered heterocycle comprising 1-2 N, O or S heteroatoms; each of which is optionally substituted with 1-2 substituents represented by R 2a; Ring B is aryl; 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms; 4-6 membered heterocycle comprising 1-2 N, O or S heteroatoms; or C 3-7 cycloalkyl; each of which is optionally substituted with 1-2 substituents independently represented by R 2a; X is -(CR 4 R 5)- or -C -; L 2 is * 2 -(CR 4 R 5) 1-2 -; * 2 -(CR 4 R 5)-C -; * 2 -(CR 4 R 5)-C -NR-; * 2 -(CR 4 R 5) 2 -O-; * 2 -(CR 4 R 5) 2 -NR-; * 2 -(CR 4 R 5) 2 -NR-SO 2 -; * 2 -(CR 4 R 5) 2 -NR-C -; * 2 -(CR 4 R 5)-C -NR-(CR 4 R 5)-; or * 2 -(CR 4 R 5) 2 -NR-C -NR-(CR 4 R 5) 0-1; wherein "* 2 " indicates the point of attachment of L 2 to N; each R 2 is independently halo, hydroxyl, C 1-6 alkyl, halo-substituted C 1-6 alkyl, -C NR 6 R 7; -S 2 -NR 4 N 5; -C O-(CR 4 CR 5) 2-3 NR 4 R 5; -N -C O-R; -SO 2 R; - NR 4 R 5 or -(CR 4 R 5)-C OR; each R 2a is independently halo, hydroxyl, C 1-6 alkyl, or halo-substituted C 1-6 alkyl; each R 3 is independently hydrogen, halo, C 1-6 alkyl, C 2-6 alkenyl or cyclopropyl; and R, R 4, R 5, R 6 and R 7 are independently hydrogen or C 1-6 alkyl; alternatively R 6 and R 7 together with N may form a 5-6 membered heterocyclic ring. R 0 is C 1-6 alkyl; C 1-6 haloalkyl; C 1-6 hydroxyalkyl; halo-substituted C 1-6 hydroxyalkyl; or phenyl optionally substituted with 1-2 substituents independently represented by R 2; or R 0 is selected from the group C 3-7 cycloalkyl, a 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms, and a 4-6 membered heterocycle comprising 1-2 N, O or S heteroatoms; each of which is optionally substituted with 1-2 substituents represented by R 2a; Ring B is aryl; 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms; 4-6 membered heterocycle comprising 1-2 N, O or S heteroatoms; or C 3-7 cycloalkyl; each of which is optionally substituted with 1-2 substituents independently represented by R 2a; X is -(CR 4 R 5)- or -C -; L 2 is * 2 -(CR 4 R 5) 1-2 -; * 2 -(CR 4 R 5)-C -; * 2 -(CR 4 R 5)-C -NR-; * 2 -(CR 4 R 5) 2 -O-; * 2 -(CR 4 R 5) 2 -NR-; * 2 -(CR 4 R 5) 2 -NR-SO 2 -; * 2 -(CR 4 R 5) 2 -NR-C -; * 2 -(CR 4 R 5)-C -NR-(CR 4 R 5)-; or * 2 -(CR 4 R 5) 2 -NR-C -NR-(CR 4 R 5) 0-1; wherein "* 2 " indicates the point of attachment of L 2 to N; each R 2 is independently halo, hydroxyl, C 1-6 alkyl, halo-substituted C 1-6 alkyl, -C NR 6 R 7; -S 2 -NR 4 N 5; -C O-(CR 4 CR 5) 2-3 NR 4 R 5; -N -C O-R; -SO 2 R; - NR 4 R 5 or -(CR 4 R 5)-C OR; each R 2a is independently halo, hydroxyl, C 1-6 alkyl, or halo-substituted C 1-6 alkyl; each R 3 is independently hydrogen, halo, C 1-6 alkyl, C 2-6 alkenyl or cyclopropyl; and R, R 4, R 5, R 6 and R 7 are independently hydrogen or C 1-6 alkyl; alternatively R 6 and R 7 together with N may form a 5-6 membered heterocyclic ring.